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ABSTRACT 
SATB2-associated syndrome (SAS) is an autosomal dominant neurodevelopmental disorder 
caused by alterations in the SATB2 gene.  Here we present a review of published pathogenic 
variants in the SATB2 gene to date and report 38 novel alterations found in 57 additional 
previously unreported individuals. Overall, we present a compilation of 120 unique variants 
identified in 155 unrelated families ranging from single nucleotide coding variants to genomic 
rearrangements distributed throughout the entire coding region of SATB2. Single nucleotide 
variants predicted to result in the occurrence of a premature stop codon were the most commonly 
seen (51/120=42.5%) followed by missense variants (31/120=25.8%). We review the rather 
limited functional characterization of pathogenic variants and discuss current understanding of 
the consequences of the different molecular alterations. We present an expansive phenotypic 
review along with novel genotype-phenotype correlations. Lastly, we discuss current knowledge 
on animal models and present future prospects. This review should help provide better guidance 
for the care of individuals diagnosed with SAS. 
 
Key Words: SATB2-Associated syndrome, SATB2, genotype-phenotype correlation, pathogenic 
variants, whole exome sequencing 
  
1. BACKGROUND 
 
SATB2-associated syndrome (SAS; Glass syndrome, MIM# 612313) is an autosomal dominant 
disorder first reported in 1989 in a 16-year-old male with severe intellectual disability and an 
interstitial deletion of 2q32.2-2q33.1 (Glass, et al., 1989). Clinically, SAS is characterized by 
developmental delay/intellectual disability with absent or limited speech development, palatal 
and dental abnormalities, feeding difficulties, behavioral problems, and dysmorphic facial 
features (Docker, et al., 2014; Zarate, et al., 2015; Zarate, et al., 2018a). Other supportive 
findings such as skeletal anomalies with low bone density and abnormal brain neuroimaging 
have been described (Zarate, et al., 2018a; Zarate, et al., 2018b).  
SAS is caused by alterations of SATB2 that can include single nucleotide variants (loss-
of-function as well as missense), intragenic deletions and duplications, contiguous deletions, and 
translocations with secondary gene disruption (Zarate and Fish, 2017; Zarate, et al., 1993). While 
haploinsufficiency of SATB2 seems the most likely mechanism of disease, a dominant negative 
effect has been suggested in at least one instance in an individual with a nonsense variant 
(Leoyklang, et al., 2013). The SATB2 gene maps to 2q32-q33 and has 3 transcripts 
(NM_001172509, NM_001172517, and NM_015265), codes for SATB2, a 82.6 kDa protein of 
733 amino acids. 
SATB2 binds to nuclear matrix-attachment regions (MARs) where it organizes chromatin 
to regulate tissue-specific gene regulatory networks (GRNs), and thus has critical roles in 
multiple developmental processes (Britanova, et al., 2006; Dobreva, et al., 2006; Dobreva, et al., 
2003; Gyorgy, et al., 2008). The SATB2 protein has two CUT domains and a homeodomain 
(FitzPatrick, et al., 2003) that are highly conserved across vertebrate taxa (FitzPatrick, et al., 
2003; Sheehan-Rooney, et al., 2010). The CUT domains and homeodomains are both DNA-
binding motifs, which may bind DNA independently or cooperatively. 
Clinically, SAS has been characterized through two large cohort studies (Bengani, et al., 
2017; Zarate, et al., 2018a). We recently presented the common clinical features and natural 
history of 72 individuals with SAS due to a variety of molecular mechanisms. In this study, we 
review the previously described individuals with SAS and present 57 additional individuals that 
expand the mutation spectrum seen in this condition and describe novel genotype-phenotype 
correlations. All families reported for the first time were enrolled under a research clinical 
registry protocol approved by the Institutional Review Board of the University of Arkansas for 
Medical Sciences.  
2. VARIANTS 
 
All SATB2 variants are described according to current HGVS mutation nomenclature guidelines 
based on Genbank accession number NM_015265 (den Dunnen, et al., 2016). Novel variants are 
interpreted using ACMG classification recommendations (Richards, et al., 2015). This report 
excludes larger deletions and duplications that encompass SATB2 along with adjacent genes.  
Tables 1 and 2 detail all 101 previously published SATB2 intragenic alterations in the 
international peer-reviewed literature (PubMed database) and the Human Gene Mutation 
Database (HGMD professional 2018.3) (Asadollahi, et al., 2014; Balasubramanian, et al., 2011; 
Baptista, et al., 2008; Bengani, et al., 2017; Boone, et al., 2016; Bowling, et al., 2017; Brewer, et 
al., 1999; Cherot, et al., 2018; Deciphering Developmental Disorders Study, 2017; Farwell, et al., 
2015; Gilissen, et al., 2014; Kaiser, et al., 2015; Kikuiri, et al., 2018; Lee, et al., 2016; 
Leoyklang, et al., 2007; Lieden, et al., 2014; Lv, et al., 2018; Rainger, et al., 2014; Rauch, et al., 
2012; Rosenfeld, et al., 2009; Schwartz, et al., 2017; Scott, et al., 2018; Talkowski, et al., 2012; 
Tegay, et al., 2009; Trakadis, et al., 2014; Vissers, et al., 2017; Zarate, et al., 2017; Zarate, et al., 
2015; Zarate, et al., 2018a; Zarate, et al., 2018b).  In this study, we also report 57 additional 
individuals with 47 SATB2 alterations (Tables 1 and 2) that have been submitted to the LOVD 
database: https://databases.lovd.nl/shared/genes/SATB2. 
Overall, including our data and those of the literature, a total of 120 unique variants were 
found in 158 individuals from 155 unrelated families. While all types of pathogenic variants 
were found, single nucleotide variants that are predicted to result in the occurrence of a 
premature stop codon were the most commonly seen (51/120=42.5%). Missense variants were 
also frequently found (25.8%), followed by intragenic deletions (18.3%), translocations (5%), 
splice site alterations (5%), intragenic duplications (2.5%), and a single in-frame alteration 
(0.8%) (Supp. Figure S1).  
2.1 Point pathogenic variants 
Eighty-nine distinct point variants including single base substitutions and small 
deletions/insertions were found in 127 individuals from 125 families (Figure 1) (Liu, et al., 
2015).  Most molecular diagnostics were performed by whole exome sequencing (WES) 
(105/127=82.7%) with the remaining individuals obtaining the diagnosis through a different next 
generation sequencing (NGS) platform (epilepsy, intellectual disability or Angelman syndrome 
dedicated panels, 11.8%), SATB2 Sanger sequencing (3.1%), or whole genome sequencing 
(WGS, 2.4%). De novo status was confirmed in almost all instances when parental testing was 
performed (98.1%, 105/107 families), including a pair of monozygotic twins. The remaining two 
instances correspond to a pair of siblings found to have the same variant indicating germline 
mosaicism and a case of low level blood mosaicism in a father of a single SAS-affected 
individual previously reported. Here, we present individual (SATB2-135) with a de novo mosaic 
pathogenic variant (c.1498delG) as determined by WES (32/143 reads) and presenting with the 
common phenotypic features.  
The 89 pathogenic variants were distributed along the entire coding sequence of SATB2, 
and while variants were present in every coding exon (exon 3-12), the distribution was not 
uniform (Supp. Figure S2A). Unique pathogenic variants found in single individuals were most 
common (Figure 1). However, 7.9% of the pathogenic variants (7/89) were seen in two to four 
different families and 4.5% (4/89) were present in five or more families. Nearly half 
(41/89=46.1%) of the pathogenic variants were found in exons 8 and 9. There was a clear 
overrepresentation of exon 9 in particular when adjusting by size of each individual exon. This 
suggests a hotspot of pathogenic variants (Supp. Figure S2B). 
2.1.1 Missense variants 
Thirty-one unique missense variants were found in 49 individuals. Most missense variants were 
located within exons 8 and 9 (19/31=61.3%, Supp. Figure S2A) and located within the CUT1 
domain (17/31=54.8%) of the SATB2 protein. Missense variants were often shared by multiple 
individuals with alterations in codons 389 (12 individuals) and 399 (7 individuals) being 
particularly common, suggesting hotspots. Most missense variants were confirmed to be de novo 
(44/45=97.8%). To assess the predicted pathogenicity of the 11 novel variants reported in this 
study, Polyphen2, SIFT, Provean, Mutation Taster, and CADD prediction programs were used 
(Supp. Table S1). Ten variants were interpreted as deleterious by all 5 programs, the remaining 
(p.Gln514Arg) with 4/5 programs predicting damaging effects.  
 
Functional studies have been performed for three missense variants: c.1165C>T, 
p.(Arg389Cys), c.1543G>A, p.(Gly515Ser), and c.1696G>A p.(Gln566Lys) (Bengani, et al., 
2017). The p.Arg389Cys change located in the CUT1 domain led to a marked increase in the 
proportion of soluble fraction of the protein while the p.Gly515Ser and p.Gln566Lys variants 
located within the CUT2 domain and the region between CUT2 and the HOX domains 
respectively, had the opposite effect.  These experiments suggested a role of the CUT1 domain in 
initiating interaction with chromatin and a requirement for the CUT2 domain to facilitate 
dissociation of SATB2 from bound chromatin. These alterations in the kinetics of chromatin 
association resulting from missense variants have been postulated to functionally result in 
alterations that resemble complete loss-of-protein function (Bengani, et al., 2017). 
2.1.2 In frame insertion 
A single de novo in frame insertion of 12 nucleotides not predicted to alter the reading frame has 
been reported in SATB2: c.929_930insTTGTAAGGCAAC, p.(Q310delinsHCKAT). The 
individual had a history of moderate to severe intellectual disability, autism, macrocephaly, 
frontal bossing, and deep-set eyes (Gilissen, et al., 2014).  
 
2.1.3 Predicted truncating variants  
Fifty-one SATB2 variants reported were predicted to be disruptive to protein production resulting 
in loss of function, including 5 nonsense and 11 frameshift novel variants from this study. The 
variants were distributed throughout the reading frame but were frequently found within exons 8 
to 12 (38/51=74.5%). Stop-gain pathogenic variants located within the last 2 exons might be 
expected to escape nonsense-mediated decay and result in a shorter protein. In keeping with this 
hypothesis, a single variant located within the last exon of SATB2 (c.2074G>T; p.Glu692*) was 
shown to result in a shorter protein consistent with the predicted 692aa protein product of the 
mutant cDNA (Bengani, et al., 2017). Two additional predicted loss-of-function variants have 
been studied in greater detail: c.715C>T (p.R239*) and c.847C>T (p.R283*) both found in six 
individuals each. The c.715C>T variant located in exon 8, was documented at the RNA level in 
two previously described unrelated individuals, indicating that the RNA was stable enough to 
escape nonsense mediated decay (NMD) (Docker, et al., 2014; Leoyklang, et al., 2007). Further, 
the translated truncated protein retained the SATB2 dimerization domain. Through luciferase 
assays using a MAR sequence binding domain, it was documented to interfere with the 
repressive MAR-regulated transcriptional activity of the wild-type SATB2, suggesting a 
dominant negative effect for this mutation (Leoyklang, et al., 2013). Conversely, the c.847C>T 
variant, also located in exon 8, was studied from tooth mesenchymal cells from an affected 
individual. Diminished SATB2 expression by Sanger sequencing and reduced SATB2 mRNA 
compared to control was demonstrated for this variant, suggesting NMD of the mutant RNA 
transcript (Kikuiri, et al., 2018). 
 
2.1.4 Splice site variants  
Six variants (1 novel from this study) disrupted an essential splice site consensus sequence: three 
affecting the donor (5’) site at the end of exons 4, 5, and 8, and three affecting the acceptor (3’) 
site at the start of exons 7, 9, and 12. Splice-prediction programs (MaxEntScan and Human 
Splicing Finder) predicted abnormal splicing for all variants and a potential activation of cryptic 
donor site or acceptor site for c.473+1delG and c.1741-1G>A, respectively. No RNA analysis 
has been performed to confirm the impact on splicing for any of these variants.  
 
2.2 Large intragenic rearrangements 
Twenty five SATB2 exonic (1 to 12 inclusive) rearrangements including 22 deletions (10 from 
this report) and 3 duplications have been described (Table 2). For the 10 individuals that 
underwent parental testing, de novo status was confirmed. A pair of siblings (SATB2-02 and 
SATB2-128) with an intragenic deletion from phenotypically unaffected parents is also reported 
here for the first time suggesting germline mosaicism. Except for one individual (SATB2-92) 
identified through WGS and another as part of subtelomere multiplex ligation-dependent probe 
hybridization (MLPA) analysis (SATB2-140), all other copy number variations were initially 
identified by chromosomal microarray performed as part of the clinical evaluation with sizes 
ranging from 10 to 317kb for deletions and between 32 and 54kb for duplications (Table 2). For 
all individuals, SATB2 was the only gene affected with no involvement of adjacent genes. Multi-
exonic rearrangements were more common (19/25=76.0%) than single exon involvement (Figure 
1). Abnormalities involving at least exon 7 were present in half of these individuals (14 total 
from 13 unrelated families). No deletions have been documented at the cDNA level and only 2 
refined by MLPA. A single duplication was studied at the cDNA level (Kaiser, et al., 2015). In 
this female individual, an initial chromosomal microarray (Cytoscan HD, Affymetrix) revealed 
an 84-kb duplication within chromosomal region 2q33.1 (200,256,583–200,340,204) 
encompassing a part of the SATB2 gene. Reverse transcription PCR analysis with cDNA primers 
flanking the duplicated exon and subsequent Sanger sequencing of the extracted cDNA 
fragments showed the tandem in-frame duplication consistent with co-expression of transcripts 
with a duplicated exon and wild-type transcripts. 
2.3 Large chromosomal rearrangements including 2q33.1 
Thirty-five individuals with larger chromosomal alterations that include 2q33.1 (33 deletions, 2 
duplications) have been reported and reviewed in the past (Zarate and Fish, 2017; Zarate, et al., 
2018a). For deletions, some of these include dozens of adjacent genes and are as large as 26.3 
Mb (Rifai, et al., 2010). While overlapping features with SAS are present in most individuals 
with larger deletions, other less common abnormalities such as genitourinary anomalies, cardiac 
defects, and ectodermal changes (other than dental) appear to be more common (or exclusively 
present) when compared to intragenic molecular alterations (Zarate and Fish, 2017). For this 
group of individuals with larger rearrangements of 2q33.1, it remains difficult to establish 
genotype/phenotype correlations given the potential phenotype contribution of other genes 
besides SATB2.  
2.4 Translocations 
The original report of two de novo apparently balanced autosomal translocations t(2;7)(q33;p21) 
and t(2;11)(q32;p14) allowed the recognition of SATB2 as the causative gene for this syndrome 
(Brewer, et al., 1999). High resolution mapping of the t(2;7) translocation showed disruption of 
the coding region of the SATB2 gene between exons 2 and 3 (FitzPatrick, et al., 2003), whereas 
t(2;11) disrupted the long-range cis regulatory elements located in the centromeric gene desert 3’ 
of SATB2 (Rainger, et al., 2014). A few additional individuals with SATB2 disruption secondary 
to de novo chromosomal translocations were subsequently described to result in SAS providing 
further supporting evidence for this molecular mechanism of disease (Baptista, et al., 2008; 
Rainger, et al., 2014; Talkowski, et al., 2012; Tegay, et al., 2009).  
3. BIOLOGICAL RELEVANCE 
SATB2 pathogenic alterations are distributed throughout the coding regions of the gene but exons 
8, 9, and 11 are most commonly involved. For missense variants, most (23/31=74.2%) are 
located within the CUT1, CUT2 or HOX DNA protein domains. While the joint function of 
these DNA binding domains is not fully clear, it is suggested that missense variants 
within the core of the CUT domain are likely to result in loss of DNA-binding activity; CUT1 
being required to initiate interaction with chromatin and CUT2 (and the region between CUT2 
and HOX)  required to facilitate dissociation of SATB2 from bound chromatin (Bengani, et al., 
2017). The vast majority of pathogenic alterations of SATB2 are null variants (frameshift, 
nonsense, canonical splice site, and single or multiexon deletions) and while predicted to result 
in a loss-of-function and haploinsufficiency, limited functional studies have suggested a potential 
dominant negative effect for some. Of note, an increasing number of missense pathogenic 
variants have been described with functional alterations that resemble the complete loss-of-
protein function.  
 
4. CLINICAL AND DIAGNOSTIC RELEVANCE 
 
A summary of clinical features of all 158 individuals previously reported and from this report, 
excluding those with larger deletions and duplications that include SATB2 and surrounding 
genes, is presented in Table 3. With rare exceptions, SAS diagnosis was not clinically recognized 
a priori. However, while the diagnosis of SAS still relies on molecular confirmation of a 
pathogenic variant in SATB2, a distinctive phenotype can often be identified. Speech delay is 
present in all individuals older than 2 years of age.  
Severe expressive language delay is common with 84.3% (102/121) of individuals older than 4 
years of age having 10 or fewer words in their expressive vocabulary, with 42.1% (51/121) 
demonstrating completely absent verbal communication (Supp. Figure S3). Other areas of 
neurodevelopment can also be compromised as evidenced by an average age at first steps of 25.5 
months. Intellectual disability has been reported in several individuals old enough to undergo 
cognitive evaluations and often in the moderate to severe range (Zarate, et al., 2018a). Dental 
abnormalities are present in all individuals and include delayed development of the mandibular 
second bicuspids or the roots of the permanent teeth, severely rotated or malformed teeth, 
taurodontism, and multiple odontomas (Kikuiri, et al., 2018; Scott, et al., 2018). Behavioral 
difficulties, feeding issues, abnormal brain neuroimaging, low bone density, suggestive facial 
features, and cleft palate complete the characteristic phenotype of SAS (Table 3). Through 
previous reports and the evaluation of dozens of patients by at least a single examiner (Y.A.Z.), 
broad thumbs and/or halluces appear to be another distinctive feature,  present in a third of 
individuals evaluated (16/47=34%), that could raise the clinical suspicion of this diagnosis 
(Figure 2A).  
Since the identification of SATB2 as the gene responsible for SAS, the number of described 
individuals has continued to grow over the last few years. Most current molecular cytogenetic 
platforms should be able to detect exon level intragenic deletions involving SATB2. Likewise, 
SATB2 is part of several commercially available panels targeting broad phenotypes such as 
developmental delay, autism, or seizures. As families receive counseling, it is important to 
discuss the potential recurrence risk considering a few instances of suspected germline 
mosaicism documented. With a previous report of coding variants in siblings and the sibling pair 
with intragenic deletions reported here, we estimate a 1-2% germline mosaicism risk (2/155 
families=1.3%). Of note, paternal blood mosaicism has also been documented in one occasion. 
Lastly, management and surveillance guidelines for SAS have been proposed and typically need 
the participation of a multidisciplinary team with heavy emphasis on pediatric dentistry and 
speech therapy (Zarate and Fish, 2017; Zarate, et al., 1993). 
5. GENOTYPE/PHENOTYPE CORRELATIONS 
Supplementary table S2 presents detailed clinical features present in each of the 158 individuals 
(114 individuals enrolled in the SAS registry and 44 additional reported in the literature). We 
identified differences in clinical characteristics by molecular mechanism. Specific changes to the 
gene were compared to all other changes, using either Chi-square or Fisher’s exact tests (when at 
least one cell had an expected count of less than 5) for categorical variables, and t-tests for 
continuous variables. While there were no differences in the average age at walking or talking, 
other clinically relevant distinctions were identified (Supp. Table S3). The proportion of 
individuals with no verbal words to communicate older than 4 years of age was lowest for 
nonsense variants (8/29=27.6%) and highest for missense pathogenic variants mutations 
(20/39=51.3%), (p=0.0496). Individuals with missense pathogenic variants were less likely to 
have cleft palate (11/49=22.5% vs 59/105=56.2% for other groups, p<0.0001) but more likely to 
have clinical seizures (14/46=30.4% vs 15/97=15.5% for other groups, p=0.0375). Conversely, 
individuals with nonsense variants had significantly fewer clinical seizures (3/35=8.6% vs 
26/108=24.1% for other groups, p=0.0474). Lastly, individuals with frameshift variants were 
more likely to have feeding difficulties (25/26=96.2% vs 64/104=61.5% for other groups, 
p=0.0007). If this difference in the prevalence of feeding difficulties is the result of a true 
biologically different mechanism for frameshift variants compared to nonsense variants or 
merely the result of an statistical anomaly, is unclear.  
To determine if facial dysmorphisms were different enough among the most common 
molecular mechanisms, 102 2D photographs from 69 individuals (19 nonsense, 31 missense, and 
19 frameshift variants) were analyzed using Face2Gene (FDNA Inc., Boston, MA) analytic tool 
vs.18.2.0. No statistically significant differences were found among the three composite images 
(Figure 2B). However, binary comparisons for each of the three groups against a respective age 
and gender matched cohort of typical individuals revealed statistically significant differences for 
all three groups (nonsense, p=0.04; missense, p=0.018; frameshift, p=0.019). 
6. ANIMAL MODELS 
 
Much of what we know about SATB2 function in human development has come from 
studies in animal models. In mice, Satb2 is expressed in tissues that are affected in SAS patients. 
During development, Satb2 is expressed in upper layer neurons, neural crest progenitors of the 
jaw, osteoblasts, odontoblasts and other dental progenitor cells (Britanova, et al., 2006; Dobreva, 
et al., 2006; He, et al., 2017). In adults, Satb2 continues to contribute to bone and brain function 
through its expression in osteoblasts and pyramidal neurons of the cerebral cortex and 
hippocampus (Huang, et al., 2013; Jaitner, et al., 2016; Wei, et al., 2012).  
In general, Satb2 functions as a transcriptional regulator that is important for tissue-
specific functions. In mice bone progenitors, Satb2 regulates osteogenic differentiation genes 
(Dobreva, et al., 2006), while in post-mitotic neurons Satb2 regulates expression of genes 
involved in upper layer identity, synaptic transmission, and axon guidance (Jaitner, et al., 2016; 
Li, et al., 2017; Whitton, et al., 2018). The consequence of loss of Satb2 in bone progenitors is 
reduced bone size and density due to increased cell death and reduced differentiation potential 
(Britanova, et al., 2006; Dobreva, et al., 2006).  
In murine brain development, Satb2 is required to specify upper layer cortical neurons 
that project axons across the corpus callosum to the contralateral hemisphere (Alcamo, et al., 
2008; Britanova, et al., 2008). Loss of Satb2 also results in reduced branches and spine density in 
basal dendrites of hippocampal neurons (Li, et al., 2017). Similar to SAS patients, Satb2+/- 
heterozygous mice have no reported corpus callosum defects (Alcamo, et al., 2008; Zarate, et al., 
2018a). However, Satb2+/- heterozygous mice suffer from impaired working and spatial memory. 
This deficit is exacerbated in mice where Satb2 has been deleted postnatally in hippocampal 
neurons (Li, et al., 2017). These mice also have difficulties in locomotion, short-term novel 
object recognition memory, and long-term contextual fear memory (Jaitner, et al., 2016; Li, et 
al., 2017). 
Taken together, research in animal systems has provided molecular and cellular 
mechanisms underlying SAS pathogenesis. These data help outline expectations of long-term 
care and provide medical practitioners with guidance about the potential spectrum of defects to 
manage in SAS patients. However, current treatments are symptom-guided, and do not 
specifically target pathogenic mechanisms. Future research is needed to further explore potential 
therapies that directly target SAS pathology. 
7. FUTURE PROSPECTS 
A key avenue of future research is the use of human induced pluripotent stem cells 
(hiPSCs) to model disease and evaluate potential treatments. hiPSCs can be generated from 
patients with defined clinical phenotypes, thus enabling in vitro cellular phenotypes to be linked 
to individual clinical presentation. Use of hiPSCs allows the pathogenic mechanisms of different 
types of mutations to be evaluated. The potential to have hiPSCs from an unaffected parent 
provides a control for genetic background, allowing molecular and cellular outcomes, including 
the effect of different mutations on SATB2 mRNA and protein levels to be efficiently compared. 
Importantly, this in vitro system allows for reasonably high throughput testing of 
pharmacological agents. 
To facilitate patient treatment, it will be important to elucidate how variability in 
individual disease pathogenesis contributes to SAS phenotypes. This variability may derive from 
the type of molecular alteration to the SATB2 locus, differences in genetic background, or even 
differences in lifestyle. Although therapies attempting to exogenously supplement reduced 
protein levels have achieved little success (Dietz, 2010), it may be possible to increase the 
endogenous amount of active protein in several ways. For example, in individuals with nonsense 
pathogenic variants, low levels of SATB2 are thought to result from nonsense mediated decay of 
prematurely terminated mRNA transcripts. Several pharmacological agents are now being used 
to promote “read-through” of stop codons, thus increasing levels of full-length mRNA 
(Baradaran-Heravi, et al., 2017; Landfeldt, et al., 2018; Roy, et al., 2016). This is an especially 
attractive avenue for treatment; however, not all nonsense mutations may be equally amenable to 
these treatments as sequences around the mutation may affect read-through activity (Bolze, et al., 
2017). The power of testing multiple different nonsense mutations in an hiPSC in vitro system 
has great potential to elucidate the details of this potential therapeutic mechanism. Of note, loss 
of function mutations may be amenable to some treatment types that would not alleviate the 
effects of dominant negative mutations. Also important to consider, knowing that SATB2 has an 
important role in early neurodevelopment as it has been demonstrated in mice models, the degree 
of correction or reversal of cognitive and speech deficits even if achieving normalization of 
SATB2 protein levels in potential human patients treated at later ages could be limited.  
SATB2 function is affected by both post-transcriptional regulation by microRNAs 
(miRNAs) and post-translational modification via sumoylation (Deng, et al., 2013; Dobreva, et 
al., 2003; Wei, et al., 2012). While miRNAs regulate amounts of SATB2 protein, sumoylation 
affects SATB2 activation potential and association with endogenous MARs in vivo (Dobreva, et 
al., 2003). Sumoylation targets SATB2 to the nuclear periphery (Dobreva, et al., 2003). 
Therefore, inhibiting sumoylation may increase the amount of active SATB2 in association with 
MARs.  
Another promising approach for treatment of SAS is to focus on modifiers that buffer or 
compensate for reductions in protein function (Chen, et al., 2016). In mice, loss of Satb2 
dysregulates the expression of multiple miRNAs involved in memory and synaptic plasticity 
(Jaitner, et al., 2016).  The effects of dietary supplementation with phospholipidic concentrates 
of krill oil and buttermilk on the expression of miRNAs in hippocampal neurons have been 
studied in murine models (Crespo, et al., 2018). Finally, neurological defects in SAS patients 
have been reported to share molecular and cellular mechanisms with other neurodevelopmental 
or neurodegenerative diseases such as schizophrenia and Alzheimer’s disease (Whitton, et al., 
2018). Therefore, similar treatments could be explored for these diseases where shared molecular 
mechanisms are identified. 
8.  CONCLUSION  
In this mutation update, we present data from 158 SAS individuals and review the current state 
of knowledge and future prospects on human SATB2 alterations. The 120 unique variants from 
155 unrelated families range from single nucleotide variations to complex genomic 
rearrangements involving the entire coding region of SATB2. While germline mosaicism has 
been found in some instances, most pathogenic variants have been confirmed to be de novo. 
Missense pathogenic variants are often found, and for those studied functionally, are predicted to 
act as loss-of-protein function pathogenic variants. Almost invariably, the diagnosis of SAS is 
made after molecular investigations are performed and for individuals with genomic coding 
variants, next generation sequencing technologies are most often used. Through our extensive 
review of individuals with SAS, we present an emerging phenotype that appears more 
recognizable with age. Our broad molecular and clinical descriptions of individuals with SATB2 
should help clinicians and families establish the diagnosis of SAS and develop future therapies.  
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FIGURE LEGENDS 
Figure 1. Schematic representation of the spectrum of SATB2 variants previously described and 
from this study. A. Splicing and coding exonic pathogenic variants. Splicing variants are 
represented along the genomic structure of SATB2 gene according to NM_015265.3 including 12 
exons (boxes) and introns (black horizontal lines). Exonic pathogenic variants are illustrated 
according to changes at the protein level (p.) by corresponding mutation types as follows: green 
squares for missense variants, red diamonds for frameshift variants, and yellow circles for 
nonsense variants. Codons 239 and 283 for nonsense (6 each), and 389 (12 individuals) and 399 
(7 individuals) for missense variants are affected by the highest number of pathogenic variants. 
Diagrams were constructed using Illustrator for Biosequence (IBS1.0.1). B. SATB2 intragenic 
rearrangements. Full boxes correspond to deletions while lighter rectangles to duplications. In 
case of recurrence of the same exon being involved, number of occurrence is indicated next to 
the rearrangement.  
Figure 2. A. Broad halluces from 4 different individuals. B. Composite images of individuals 
with nonsense, missense, and frameshift variants. Across all 3 images a flat philtrum with thin 
vermillion of the upper lip can be recognized.   
 
 
